

Shri. Vile Parle Kelavani Mandal's

Institute of Pharmacy, Dhule Survey No. 499/1, Plot No.3, Behind Gurudwara, Mumbai Agra Highway

| | | U | | gnway | |
|--------------|---|---|-------------|-----------|------|
| | First Sessional Theory Exam | ination 2020-202 | 21 | | |
| Subje | • | | | 20/10/ | 2020 |
| • | Analysis | • | | | |
| Class | • | Semester | : | VII | |
| Time | | | | 30 | |
| TIME | <i>Instructions: 1. All questions are compulsory.</i> | | • | 00 | |
| | | | | | |
| | 2. Draw a well labelled diagram | | | | |
| 0.1 | 3. Right hand side number indica | iles juii marks | | | [10] |
| | Multiple Choice Questions | | | | [10] |
| 1 | Evanscent wave are observed in | | | | |
| | a. UV Visible spectroscopy | b. IR spectroscopy | | | |
| | c. Atomic emission spectroscopy | | | | |
| ii | "-COOH" is an example of acidic auxochrome | e is also c/as auxo | och | rome. | |
| | a. Positive | h Nogotivo | | | |
| | | b. Negative d. All of the above | | | |
| ::: | c. Neutral | | | | |
| iii | The ratio between distance travelled by samp | ble component and its | | | |
| | corresponding standard are called as | 1 | | | |
| | a. R _f Value | b. R_x Value | | | |
| | c. solvent front | d. a & b both | | | |
| iv | Golay cells is type of detector us | | | | |
| | a. Photo conductivity | b. Thermal dete | | | |
| | c. Photoelectric | d. Semiconduct | | | |
| v | Beer's law fails to describe absorbance behav | rior of solution above _ | | | |
| | concentration | | | | |
| | | . 0.1 M | | | |
| | | . 10 M | | | |
| vi | Wavenumbers are expressed in | | | | |
| | a) Hz | b) cm | | | |
| | c) cm/sec | d) cm ⁻¹ | | | |
| vii | Radial / Circular development technique can | be observed in | | | |
| | chromatography. | | | | |
| | | . Thin-Layer | | | |
| | - | . None of the above | | | |
| viii | Lambert-Beer's law can be mathematically gi | ven as | | | |
| | a. I _t =1 ₀ -Kt b | Log(I/I) = 0.01 | | | |
| | | . Log (I_o/I_t) = a.c.t . All of above | | | |
| : | The quantum mechanical energy levels obser | | | those | |
| 1X | of | ved in iK spectroscopy | a | le those | |
| | | . Electronic Transitio | 10 0 | | |
| | | . None of the above | ns | | |
| | | | 1 | a mba maa | |
| х | When small change in concentration produce is called as | a greater change in a | 080 | or parice | |
| | | Negotine deviction | | | |
| | | . Negative deviation . None of the above | | | |
| | c. No deviation d | . Notice of the above | | | |
| \mathbf{O} | Answer the following about questions (any ty | 10) | | | [10] |
| Q.2. | Answer the following short questions (any tu | | ~~~~ | mbre | [10] |
| a | Outline the principle, method and application | | gra | ipny. | |
| b | Distinguish between fluorescence and phosp | | | | |
| с | Write short note on atomic absorption spectr | oscopy. | | | |
| Q.3. | Answer in detail of following (any one) | | | | [10] |
| а | Define EMR? Explain in detail about principl | e, instrumentation inv | olv | red in | - |
| | UV-Visible spectroscopy. Add a note on vario | | | | |
| | transitions. | JI | | | |
| b | Describe the principle, instrumentation and a | applications of ID appa | tro | 800017 | |
| U | | applications of its spec | τυ | scopy. | |
| | Add note on FTIR. | | | | |



Approved by AICTE, PCI, DTE, Affiliated to DBATU Lonere, MSBTE Mumbai

Vision: To pursue excellence in pharmaceutical education and research to develop competent professionals.

🖾 iopdhule@svkm.ac.in

| | | First Sessional Theory Exami | nation-(ODD | S | EM) : | 2023-202 | 24 | |
|---------|---|----------------------------------|-------------|---|-------|-----------|-----------|-----|
| Subject | : | Instrumental Methods of Analysis | Day & Date | : | Mor | n 30/10/2 | 023 | |
| | | (BP701T) | | | | | | |
| Class | : | Final Year B. Pharmacy | Semester | : | VII | Write Yo | ur Seat I | No. |
| Time | : | 02:30 pm – 04:00 pm | Max. Marks | : | 30 | Here | |] |

| | 1. All questions are compulsory | 2. Draw a well labeled diagram wherever necessary | j |
|--------------|---|---|------|
| Instructions | 3. Right hand side number indicates full marks | 4. Do not write/tick on the question paper | |
| Q. I. Solv | e the following questions | 10 | Μ |
| 1. I | Draw the schematic diagram of double beam UV | / spectrophotometer (CO1, LL3). | |
| 2. 5 | State the Beers-Lambert's law and give its equa | tion? (CO1, LL3). | |
| 3. I | Determine the concentration of the solution if, sp | pecific absorbance, $A^{1\%}_{1 \text{ cm}} = 540$ at 241 nm, $A = 0.8$ | 890, |
| ł | b =1 cm. (CO1, LL5). | | |
| 4. I | Differentiate between Nephelometry and Turbid | imetry (CO2, LL3). | |
| 5. | Write the principle of gel electrophoresis (CO2, | LL3). | |
| Q. II. | Long Answers Question (Answer any 1 out of | f 2) (CO2, LL5) 10 |) M |
| 1. I | Explain the sampling techniques and instrument | ation in IR spectroscopy. | |
| 2. I | Explain the principle, instrumentation and applied | cations of Atomic Absorption Spectroscopy. | |
| Q. III. | Short Answers Question (Answer any 2 out o | f 3) (CO1, LL5) 10 |) M |
| 1. I | Explain the different electronic transitions that o | ccur in molecules after absorbing UV visible radiati | ions |
| 2. I | Explain the principle of fluorimetry using Jablon | nski diagram | |
| 3. I | Explain the types of quenching and factors respo | onsible for quenching. | |



Behind Gurudwara, Mumbai-Agra Highway, Dhule Phone: 02562- 297802, 297805 Fax: 02562- 287802, Email: examiop@svkm.ac.in

First Sessional Examination 2020-2021 (ODD SEM)

Subject & Subject Code: Industrial Pharmacy II BP 702T **Class: Final Year B. Pharm** Time:1.30 - 3.00pm

Day & Date: Tuesday 21/10/2020 Semester: VII Max. Marks: 30

10

1. All questions are compulsory Instructions:

2. Draw a well labeled diagram wherever necessary 3. Right hand side number indicates full marks

QI Multiple Choice Questions (MCQs)

- 1. Ouality Risk Management (ORM) is mentioned in ICH guidelines..... a. Q7, b. Q8, c. Q9, d. Q10
- 2. Innovation is defined as:
 - a) the commercialization of a new product or process.
 - b) the invention of a new product or process.
 - c) a new product or process idea.
 - d) the implementation of a new production method.
- 3. Which of the following is not in India
- a. APCTT. b. TBSE c. NDRC, d. NIST
- 4. SUPAC-MR Focus on
 - a. Changes for amount of excipients in the drug product.b. Changes in non-release controlling excipients.

 - c. Changes in release controlling excipients.d. change in the amount of the drug substance
- 5. Technological and commercial merit of IP should be assessed at a very early stage in order that successful commercialization can occur
 - a. True b. False
- 6. The owner of a technological IP is called
- a. Licensee b. Licensor c. License d. None of above
- 7. Laboratory scale batch is generally..... than production batch
 - a. 100-1000 times less b. 10-100 times less
 - C. 1000-10000 times less d. 100-10000 times less
- 8. Small industrial development bank of India (SIDBI) was established on.... a. April2, 1990 b. April2, 1991 c. April2, 1992 d. April2, 1993
- 9. The transfer of technology between sites of different companies is called as
 - a. Inter-company transfer, b. Intra-company transfer, c. intra site technology transfer d. None of these
- 10 In Exclusive license, a single licensee has the right to use the intellectual property, which cannot even be used by the owner. An exclusive license permits only the licensee and persons authorized by the licensee to exploit the invention
 - a. True b. False

QII Long Answers (Answer any 1 out of 2)

1. What is regulatory affairs? Explain roles and responsibility of regulatory affair professionals. 2. Explain objectives and significance of pilot plant. Discuss general considerations for pilot plant scaleup of liquid dosage form.

QIII Short Answers (Answer any 2 out of 3)

- 1. Write short note on WHO guidelines for Technology Transfer.
- 2. Discuss various approved regulatory bodies and agencies for technology transfer agencies in India.
- 3. Write a note on guidelines or SUPAC-IR.

10



Approved by AICTE, PCI, DTE, Affiliated to DBATU Lonere, MSBTE Mumbai

Vision: To pursue excellence in pharmaceutical education and research to develop competent professionals.

🖾 (02562) 297802, 297602 🛛 🌐 www.svkm-iop.ac.in

⊠ iopdhule@svkm.ac.in

10 M

10 M

| | First Sessional Theory Exami | ination-(ODD SEM) 2023-2024 |
|--------------|--|---|
| Subject | : Industrial Pharmacy-II (BP702T) | Day & Date : Tuesday, |
| Class | : Final Year B. Pharmacy | 31/10/2023 Semester : VII |
| A . | : 2:30 to 4:00PM | Max. Marks : 30 |
| | 1. All questions are compulsor ructions: 2. Draw a well labeled diagra 3. Right hand side number in ive Type Questions (5 x 2) = 5 x 2 = | um wherever necessary dicates full marks |
| 1. What is S | SUPAC | (CO1, LL2) |
| 2. Write GM | MP Consideration for Pilot Plant Scale-up | (CO1, LL2) |
| 3. Define | | (CO1, LL1, CO2, LL1) |
| | a. Scalability | b. Drug master file |
| 4. What is I | Platform technologies | (CO2, LL5) |

5. Define the Tech Transfer process as per WHO (CO2, LL5)

- QII Long Answers Question (Answer any 1 out of 2) (CO1, LL4)
- 1. Enumerate in detail the various considerations for Solid dosage forms under Pilot plant scale-up
- 2. Enlist Pilot plant scale-up activities, Objectives, and Significance. Write in detail about
 - 1. SUPAC guidelines
 - 2. Platform Technology

QII Short Answers Question (Answer any 2 out of 3) (CO2, LL4)

- 1. Enlist various parameters of the Technology transfer protocol. Write in brief about documentation.
- 2. Write in short about the TT agencies in India
- 3. Explain in brief about Premises and Equipment in technology transfer



Approved by AICTE, PCI, DTE, Affiliated to DBATU Lonere, MSBTE Mumbai

Vision: To pursue excellence in pharmaceutical education and research to develop competent professionals.

☎ (02562) 297802, 297602 www.svkm-iop.ac.in

⊠ iopdhule@svkm.ac.in

| | ⊡ (02302) 297802, 297002 | | |
|-------------------|--|---|--------------|
| Subject : | First Sessional Theory Examina Industrial Pharmacy-II (BP702T) | Day & Date : Tuesda | у, |
| Class : Time : | Final Year B. Pharmacy 2:30 to 4:00PM | Semester : VII Max. Marks : 30 | 2023 |
| | 1. All questions are compulsoryctions:2. Draw a well labeled diagram u3. Right hand side number indicave Type Questions (5 x 2) = 5 x 2 = 10 | tes full marks | 10 M |
| 1. What is S | JPAC | (| CO1, LL2) |
| 2. Write GM | P Consideration for Pilot Plant Scale-up | (CO | 1, LL2) |
| 3. Define | | (CO1, LL1 | , CO2, LL1) |
| | a. Scalability | b. Drug master file | |
| 4. What is Pl | atform technologies | (0 | CO2, LL5) |
| 5. Define the | Tech Transfer process as per WHO | (C) | 02, LL5) |
| QII Long | Answers Question (Answer any 1 out of 2) (C | 01, LL4) | 10 M |
| 1. Enume | erate in detail the various considerations for Soli | id dosage forms under Pilot plant scale | e-up |
| 2. Enlist | Pilot plant scale-up activities, Objectives, and S | ignificance. Write in detail about | |
| 1. | SUPAC guidelines | | |
| | - | | |
| 2. | Platform Technology | | |
| QII Short | Answers Question (Answer any 2 out of 3) (C | CO2, LL4) | 10 M |
| 1 514 | unious commeters of the Taskasle on transfer a | | , , . |

- 1. Enlist various parameters of the Technology transfer protocol. Write in brief about documentation.
- 2. Write in short about the TT agencies in India
- 3. Explain in brief about Premises and Equipment in technology transfer



Behind Gurudwara, Mumbai-Agra Highway, Dhule Phone: 02562- 297802, 297805 Fax: 02562- 287802, Email: examiop@svkm.ac.in

First Sessional Theory Examination 2020-2021 (Odd SEM)

Subject & Subject Code: Novel Drug Delivery System (BP 704T)

Day & Date: Friday, 23/10/2020

Class: Final Year B.Pharm

Time: 1.30 – 3.00 pm

Semester: VII Max. Marks: 30

Instructions: 1. All questions are compulsory

2. Draw a well labeled diagram wherever necessary 3. Right hand side number indicates full marks

QI Multiple Choice Questions (MCQs)

1. Selection criteria of drug for CRDDS depends upon which pharmacokinetic parameter

- a. Therapeutic Index
- b. PK/PD relationship
- c. Half Life
- d. Partition coefficient

2. Which type of drug delivery system will referred as "Smart Drug Delivery System"?

- a. Controlled Drug Delivery System
- b. Sustained Drug Delivery System
- c. Extended Drug Delivery System
- d. Targeted Drug Delivery System
- 3. Type of polymer display better solvent permeability / solubility is
 - a. Cross linked Polymer
 - b. Branched Polymer
 - c. Linear Polymer
 - d. Thermoplastic polymer
- 4. The matrix system used in diffusion approach were made up of
 - a. Soluble Polymer
 - b. Insoluble Polymer
 - c. Erodible Polymer

d. Impermeable Polymer with Pores

- 5. Magnesium sulphate were used as osmogen in which type of osmotic pump
 - a. Rose Nelson osmotic pump
 - b. Higuchi Leeper osmotic pump
 - c. Higuchi Theeuwes osmotic pump
 - d. Parentral osmotic pump
- 6. Fluidization of core particle is principle of which method of microencapsulation



Behind Gurudwara, Mumbai-Agra Highway, Dhule Phone: 02562- 297802, 297805 Fax: 02562- 287802, Email: examiop@svkm.ac.in

- a. Coacervation phase separation
- b. Spray drying
- c. Spray congealing

d. Air suspension technique

7. Theory describes interpenetration of the mucoadhesive polymer and substrate to create semipermenant adhesive bond is

a. Wetting theory

b. Diffusion theory

- c. Electronic theory
- d. Fracture theory

8. Most widely used chemical penetration enhancer leads to denaturation of skin protein in TDDS devise is

- a. Propylene Glycol
- b. Dimethyl acetamide
- c. Dimethyl Sulfoxide
- d. Air suspension technique

9. A process of transdermal drug delivery system use voltage gradient to transfer ionic drug molecule is

a. Iontophoresis

- b. Sonophoresis
- c. Electroporation
- d. Laser ablation

10. Types of system contain drug with gel-forming hydrocolloids, which allow them to remain buoyant on the stomach content

- a. High density GRDDS
- b. Gastro-adhesive GRDDS

c. Floating drug delivery system

d. Inflatable drug delivery system

QII Long Answers (Answer any 1 out of 2)

1. Describe in detail about Air Suspension Technique & Spray Drying method of Microencapsulation.

2. Give classification of controlled release drug delivery system and Explain in brief about selection criteria of drug for CRDDS.

QIII Short Answers (Answer any 2 out of 3)

1. Explain in detail about Diffusion approach for design of CRDDS.

- 2. Confer in brief about types of osmotic pump or theories of mucoadhesion
- 3. Elucidate in detail about formulation approach of Transdermal drug delivery system device.

10



Behind Gurudwara, Mumbai-Agra Highway, Dhule Phone: 02562- 297802, 297805 Fax: 02562- 287802, Email: examiop@svkm.ac.in

Mapping of Course Outcome with First Sessional Exam

| Course Outcome | Question | Marks |
|---|------------------------------------|-------|
| CO 7041: Outline and discuss the basic components and formulation approaches for Novel Drug Delivery System viz CDDS, TDDS, GRDDS, Nasopulmonary and Ocular therementies. Level 2 (Computed properties) | Q.1 – 2,3,4,8,9,10 Q 3 – 1,3 | 16 |
| therapeutics - Level 2 (Comprehension) CO 7042: Demonstrate the criteria for selection of drug and polymer to design various Novel Drug Delivery System - Level 3 (Application) | Q 1 - 1 Q 2 - 2 | 11 |
| CO 7043: Illustrate the concept, theories, development and types of osmotic pump, occular inserts, intrauterine devices, mucosal DDS and methods of microencapsulation - Level 4 (Analysis) | Q.1 - 5,6,7 Q 2 - 1 Q 3 - 2 | 18 |

First Sessional Theory Examination 2021-2022

Subject: Novel drug delivery system (BP704T)Day & Date: Thursday&14/10/2021Class: Final Year B.PharmSemester: VIITime: 10.30 am – 12.00 pmMax. Marks: 30

Instructions: 1. All questions are compulsory 2. Draw a well labeled diagram wherever necessary 3. Right hand side number indicates full marks 10 **QI Multiple Choice Questions (MCQs):** 1. In which delivery system the formulation is retained in the stomach a. Site-specific drug delivery system b. Controlled drug delivery system c. Oral drug delivery system d. Gastro-retentive drug delivery system 2. Density of gastric content is g/cm² a. 2.005 b. 1.004 b. 3.005 d. 5.004 3. The body's natural immune system is used in which type of targeting. b) Passive a) Active c) physical d) Dual 4. Size range of liposome is a. 25-5000nm b. 1-100nm **c.** 10-100nm d. 5000-10000nm 5. Pilo 20 is marketed preparation of b. SODI d. Minidisc a. lacrisert c. Ocusert 7. Pre-corneal constrain is a. lacrimation b. tear dilution c. solution drainage d. All of the above 8. First IUD was developed in the year a. 1890 b. 1960 c. 1909 d. 1920 9. Copper-T is useful in a. Contraception b. Auto-immune disease c. Copper deficiency d. Both b & c 10. Chitosan is which type of polymer used in ionotropic gelatin microencapsulation technique? a. Natural b. Synthetic c. Semisynthetic d. None of the above

Q.II Long Answers (Answer any 1 out of 2)

1. Explain the concept of targeted drug delivery system. State its advantage and dis-advantage. Write note on Liposomes.

2. Illustrate the application of targeted drug delivery system and write note on Nanoparticles.

Q.III Short Answers (Answer any 2 out of 3)

1. Write in brief various approaches for Gastro-retentive drug delivery system

2. Write note on Inhalers.

3. State various Intraocular barriers.

10



Shri Vile Parle Kelavani Mandal's **INSTITUTE OF PHARMACY, DHULE** Behind Gurudwara, Mumbai-Agra Highway, Dhule

Phone: 02562- 297802, 297805 Fax: 02562- 287802, Email: examiop@svkm.ac.in

First Sessional Theory Examination 2021-2022

Subject: Novel drug delivery system (BP704T) Class: Final Year B.Pharm Time: 10.30 am – 12.00 pm Day & Date: Thursday&14/10/2021 Semester: VII Max. Marks: 30

10

Instructions: 1. All questions are compulsory

2. Draw a well labeled diagram wherever necessary

3. Right hand side number indicates full marks

QI Multiple Choice Questions (MCQs):

1. Selection criteria of drug for SRDDS depends upon which pharmacokinetic parameter a. Therapeutic Index b. PK/PD relationship c. Half Life d. partition coefficient

- Which type of drug delivery system will referred as "Smart Drug Delivery System"?
 a. Sustained drug delivery system
 b. Controlled drug delivery system
 d. Extended drug delivery system
- 3. The type of polymer display better solvent permeability / solubility is
 - a. Cross linked Polymer b. Branched Polymer
 - b. Linear Polymer d. Thermoplastic polymer
- 4. Which of the following characteristics is suitable for transdermal drug delivery system?a) Large drug doseb) Large molecular size
 - c) Drugs with narrow therapeutic indices d) Drugs which are metabolized in the skin

5. The type of copolymer formed by the reaction of linear polymer with monomeric unit is known as

- a. Graft copolymer b. Random copolymer
- c. Alternate copolymer d. Block copolymer
- 6. Solvent evaporation is which type of microencapsulation technique a. Chemical b. Physical c. Physico-chemical d. None
- 7. Following are the theories of microencapsulation
 - a. Wetting theory b. adsorption theory
 - c. Fracture theory d. Diffusion theory
- 8. Nitro-dur is used for

a. Contraception b. Diabetes c. Angina pectoris d. Ocular therapy

- 9. Factors affecting mucoadhesion are
 - a. Flexibility of polymer chain b. Mucin turn over
 - c. pH of substrate polymer interfaced. d. All of the above
- 10. Chitosan is which type of polymer used in ionotropic gelatin microencapsulation technique?
 - a. Natural b. Synthetic c. Semisynthetic d. None of the above

Q.II Long Answers (Answer any 1 out of 2)

1. Classify sustained release drug delivery system based on design approach. Explain in detail about selection criteria of drug for Controlled drug delivery system.

2. Elucidate in detail the four types of formulation approaches for Transdermal drug delivery devices

Q.III Short Answers (Answer any 2 out of 3)

1. Explain the Air suspension technique of microencapsulation.

2. Write the theories have been proposed to explain the fundamental mechanism of bio-adhesion /muco-adhesion.

3. Discuss in brief about osmotic pump.

10



Behind Gurudwara, Mumbai-Agra Highway, Dhule Phone: 02562- 297802, 297805 Fax: 02562- 287802, Email: examiop@svkm.ac.in

| Second Sessional Theo Subject: Novel drug delivery system (BP704T) Class: Final Year B.Pharm Time: 1.30 pm – 3.00 pm | Dry Examination 2021-2022 Day & Date: Thursday &16/12/2021 Semester: VII Max. Marks: 30 |
|---|--|
| Instructions: 1. All questions are compulsory 2. Draw a well labeled diagram wherever n 3. Right hand side number indicates full ma | |
| QI Multiple Choice Questions (MCQs): | 10 |
| 1. In which delivery system the formulation is retained in | n the stomach |
| a. Site-specific drug delivery system | c. Oral drug delivery system |
| b. Controlled drug delivery system | d. Gastro-retentive drug delivery system |
| 2. Density of gastric content is g/cm^2 | |
| a. 2.005 b. 1.004 | |
| c. 3.005 d. 5.004 | |
| 6. Pre-corneal constrain is a.lacrimation b. tear dilution c. solution drainage d. All of the above 7. First IUD was developed in the year a.1890 b. 1960 c. 1909 d. 1920 8. Copper-T is useful in a.Contraception b. Auto-immune disease c. Copper deficiency d. Both b & c 9. Which of the following is not an advantage of Dry power a. Propellant Free b. Greater Dose accuracy c. Lesser 10. Bile salts like sodium deoxycholate, Sodium glycoch | Minidisc wder inhaler? formulation problems d. Greater Chemical Stability |
| Q.II Long Answers (Answer any 1 out of 2) | 10 |
| Explain the concept of targeted drug delivery sys on Liposomes. Illustrate the application of targeted drug delivery syst | tem. State its advantage and dis-advantage. Write note em and write note on Nanoparticles. |
| O III Short Answers (Answer any 2 aut of 2) | 10 |
| Q.III Short Answers (Answer any 2 out of 3) 1.Write in brief various approaches for Gastro-retentive of 2. Write note on Inhalers. 3. State various Intraocular barriers. | 10 drug delivery system |

First Sessional Theory Examination 2021-2022

Subject: Novel drug delivery system (BP704T) Day & Date: Thursday&14/10/2021 Semester: VII Class: Final Year B.Pharm Max. Marks: 30 Time: 10.30 am – 12.00 pm

Instructions: 1. All questions are compulsory

2. Draw a well labeled diagram wherever necessary

3. Right hand side number indicates full marks

QI Multiple Choice Questions (MCQs):

- 1. Selection criteria of drug for SRDDS depends upon which pharmacokinetic parameter Therapeutic Index b. PK/PD relationship c. Half Life d. partition coefficient a. Which type of drug delivery system will referred as "Smart Drug Delivery System"? 2.
- b. Controlled drug delivery system Sustained drug delivery system a. d. Extended drug delivery system c. Targeted drug delivery system
- 3. The type of polymer display better solvent permeability / solubility is
 - b. Branched Polymer a. Cross linked Polymer
 - b. Linear Polymer d. Thermoplastic polymer
- Which of the following characteristics is suitable for transdermal drug delivery system? 4. a) Large drug dose b) Large molecular size
 - c) Drugs with narrow therapeutic indices d) Drugs which are metabolized in the skin
- 5. The type of copolymer formed by the reaction of linear polymer with monomeric unit is known as
 - a. Graft copolymer b. Random copolymer
 - Alternate copolymer d. Block copolymer c.
- 6. Solvent evaporation is which type of microencapsulation technique
- c. Physico-chemical d. None a. Chemical b. Physical Following are the theories of microencapsulation 7.
 - a. Wetting theory b. adsorption theory
 - c. Fracture theory d. Diffusion theory
- 8. Nitro-dur is used for
 - a. Contraception b. Diabetes c. Angina pectoris d. Ocular therapy
- 9. Factors affecting mucoadhesion are
 - a. Flexibility of polymer chain b. Mucin turn over
 - c. pH of substrate polymer interfaced. d. All of the above
- 10. Chitosan is which type of polymer used in ionotropic gelatin microencapsulation technique?
 - a. Natural b. Synthetic c. Semisynthetic d. None of the above

Q.II Long Answers (Answer any 1 out of 2)

1. Classify sustained release drug delivery system based on design approach. Explain in detail about selection criteria of drug for Controlled drug delivery system.

2. Elucidate in detail the four types of formulation approaches for Transdermal drug delivery devices

Q.III Short Answers (Answer any 2 out of 3)

1. Explain the Air suspension technique of microencapsulation.

2. Write the theories have been proposed to explain the fundamental mechanism of bio-adhesion /mucoadhesion.

3. Discuss in brief about osmotic pump.

10

10



Shri Vile Parle Kelavani Mandal's **INSTITUTE OF PHARMACY, DHULE** Behind Gurudwara, Mumbai-Agra Highway, Dhule

Phone: 02562- 297802, 297805 Fax: 02562- 287802, Email: examiop@svkm.ac.in

First Sessional Theory Examination 2021-2022

Subject: Novel drug delivery system (BP704T) Class: Final Year B.Pharm Time: 10.30 am – 12.00 pm Day & Date: Thursday&14/10/2021 Semester: VII Max. Marks: 30

10

Instructions: 1. All questions are compulsory

2. Draw a well labeled diagram wherever necessary

3. Right hand side number indicates full marks

QI Multiple Choice Questions (MCQs):

1. Selection criteria of drug for SRDDS depends upon which pharmacokinetic parameter a. Therapeutic Index b. PK/PD relationship c. Half Life d. partition coefficient

- Which type of drug delivery system will referred as "Smart Drug Delivery System"?
 a. Sustained drug delivery system
 b. Controlled drug delivery system
 d. Extended drug delivery system
- 3. The type of polymer display better solvent permeability / solubility is
 - a. Cross linked Polymer b. Branched Polymer
 - b. Linear Polymer d. Thermoplastic polymer
- 4. Which of the following characteristics is suitable for transdermal drug delivery system?a) Large drug doseb) Large molecular size
 - c) Drugs with narrow therapeutic indices d) Drugs which are metabolized in the skin

5. The type of copolymer formed by the reaction of linear polymer with monomeric unit is known as

- a. Graft copolymer b. Random copolymer
- c. Alternate copolymer d. Block copolymer
- 6. Solvent evaporation is which type of microencapsulation technique a. Chemical b. Physical c. Physico-chemical d. None
- 7. Following are the theories of microencapsulation
 - a. Wetting theory b. adsorption theory
 - c. Fracture theory d. Diffusion theory
- 8. Nitro-dur is used for

a. Contraception b. Diabetes c. Angina pectoris d. Ocular therapy

- 9. Factors affecting mucoadhesion are
 - a. Flexibility of polymer chain b. Mucin turn over
 - c. pH of substrate polymer interfaced. d. All of the above
- 10. Chitosan is which type of polymer used in ionotropic gelatin microencapsulation technique?
 - a. Natural b. Synthetic c. Semisynthetic d. None of the above

Q.II Long Answers (Answer any 1 out of 2)

1. Classify sustained release drug delivery system based on design approach. Explain in detail about selection criteria of drug for Controlled drug delivery system.

2. Elucidate in detail the four types of formulation approaches for Transdermal drug delivery devices

Q.III Short Answers (Answer any 2 out of 3)

1. Explain the Air suspension technique of microencapsulation.

2. Write the theories have been proposed to explain the fundamental mechanism of bio-adhesion /muco-adhesion.

3. Discuss in brief about osmotic pump.

10



Behind Gurudwara, Mumbai-Agra Highway, Dhule Phone: 02562- 297802, 297805 Fax: 02562- 287802, Email: examiop@svkm.ac.in

| Second Sessional Theo Subject: Novel drug delivery system (BP704T) Class: Final Year B.Pharm Time: 1.30 pm – 3.00 pm | Dry Examination 2021-2022 Day & Date: Thursday &16/12/2021 Semester: VII Max. Marks: 30 |
|---|--|
| Instructions: 1. All questions are compulsory 2. Draw a well labeled diagram wherever n 3. Right hand side number indicates full ma | |
| QI Multiple Choice Questions (MCQs): | 10 |
| 1. In which delivery system the formulation is retained in | n the stomach |
| a. Site-specific drug delivery system | c. Oral drug delivery system |
| b. Controlled drug delivery system | d. Gastro-retentive drug delivery system |
| 2. Density of gastric content is g/cm^2 | |
| a. 2.005 b. 1.004 | |
| c. 3.005 d. 5.004 | |
| 6. Pre-corneal constrain is a.lacrimation b. tear dilution c. solution drainage d. All of the above 7. First IUD was developed in the year a.1890 b. 1960 c. 1909 d. 1920 8. Copper-T is useful in a.Contraception b. Auto-immune disease c. Copper deficiency d. Both b & c 9. Which of the following is not an advantage of Dry power a. Propellant Free b. Greater Dose accuracy c. Lesser 10. Bile salts like sodium deoxycholate, Sodium glycoch | Minidisc wder inhaler? formulation problems d. Greater Chemical Stability |
| Q.II Long Answers (Answer any 1 out of 2) | 10 |
| Explain the concept of targeted drug delivery sys on Liposomes. Illustrate the application of targeted drug delivery syst | tem. State its advantage and dis-advantage. Write note em and write note on Nanoparticles. |
| O III Short Answers (Answer any 2 aut of 2) | 10 |
| Q.III Short Answers (Answer any 2 out of 3) 1.Write in brief various approaches for Gastro-retentive of 2. Write note on Inhalers. 3. State various Intraocular barriers. | 10 drug delivery system |

First Sessional Theory Examination 2021-2022

Subject: Novel drug delivery system (BP704T) Day & Date: Thursday&14/10/2021 Semester: VII Class: Final Year B.Pharm Max. Marks: 30 Time: 10.30 am – 12.00 pm

Instructions: 1. All questions are compulsory

2. Draw a well labeled diagram wherever necessary

3. Right hand side number indicates full marks

QI Multiple Choice Questions (MCQs):

- 1. Selection criteria of drug for SRDDS depends upon which pharmacokinetic parameter Therapeutic Index b. PK/PD relationship c. Half Life d. partition coefficient a. Which type of drug delivery system will referred as "Smart Drug Delivery System"? 2.
- b. Controlled drug delivery system Sustained drug delivery system a. d. Extended drug delivery system c. Targeted drug delivery system
- 3. The type of polymer display better solvent permeability / solubility is
 - b. Branched Polymer a. Cross linked Polymer
 - b. Linear Polymer d. Thermoplastic polymer
- Which of the following characteristics is suitable for transdermal drug delivery system? 4. a) Large drug dose b) Large molecular size
 - c) Drugs with narrow therapeutic indices d) Drugs which are metabolized in the skin
- 5. The type of copolymer formed by the reaction of linear polymer with monomeric unit is known as
 - a. Graft copolymer b. Random copolymer
 - Alternate copolymer d. Block copolymer c.
- 6. Solvent evaporation is which type of microencapsulation technique
- c. Physico-chemical d. None a. Chemical b. Physical Following are the theories of microencapsulation 7.
 - a. Wetting theory b. adsorption theory
 - c. Fracture theory d. Diffusion theory
- 8. Nitro-dur is used for
 - a. Contraception b. Diabetes c. Angina pectoris d. Ocular therapy
- 9. Factors affecting mucoadhesion are
 - a. Flexibility of polymer chain b. Mucin turn over
 - c. pH of substrate polymer interfaced. d. All of the above
- 10. Chitosan is which type of polymer used in ionotropic gelatin microencapsulation technique?
 - a. Natural b. Synthetic c. Semisynthetic d. None of the above

Q.II Long Answers (Answer any 1 out of 2)

1. Classify sustained release drug delivery system based on design approach. Explain in detail about selection criteria of drug for Controlled drug delivery system.

2. Elucidate in detail the four types of formulation approaches for Transdermal drug delivery devices

Q.III Short Answers (Answer any 2 out of 3)

1. Explain the Air suspension technique of microencapsulation.

2. Write the theories have been proposed to explain the fundamental mechanism of bio-adhesion /mucoadhesion.

3. Discuss in brief about osmotic pump.

10

10



Approved by AICTE, PCI, DTE, Affiliated to DBATU Lonere, MSBTE Mumbai

Vision: To pursue excellence in pharmaceutical education and research to develop competent professionals.

窗 (02562) 297802, 297602

www.svkm-iop.ac.in

 \square iopdhule@svkm.ac.in

First Sessional Theory Examination-(ODD SEM) 2023-2024

| Subject | : | Novel Drug Delivery Systems (BP704T) | Day & Date | : | Thur | sday, | 02/11/2023 |
|--------------|----------|--------------------------------------|--|---|------|---------------|---------------|
| Class | •• | Final Year B.Pharm | Semester | : | VIII | Write Here | Your Seat No. |
| Time | : | 2.30 pm – 4.00 pm | Max. Marks | : | 30 | пеге | |
| Instructions | 1. 3. | | 2. Draw a well label 4. Do not write/tick o | | | | |

| QI | Objective Type Questions $(5 \times 2) = 5 \times 2 = 10$ (Answer all the questions) | 10 M |
|-------------------|--|-----------------|
| 1. | Give the significance of elimination half-life $(t_{1/2})$ in design of controlled release formulation. (<i>LL3, CO1</i>) | |
| 2. | Differentiate the type of copolymer based on degree of reactivity between monomer. (<i>LL4, CO1</i>) | |
| 3. | Define the term :- i) Controlled Release (<i>LL1, CO1</i>) ii) Microencapsulation (<i>LL1, CO2</i>) | |
| 4. | Explain the principal difference between spray drying and spray congealing or Explain diffusion of drug by iontophoresis principle of permeation enhancement. (<i>LL3, CO2</i>) | |
| 5. | Enlist the principle involved in release of drug for implantable delivery system (<i>LL3</i> , <i>CO2</i>) | |
| | | |
| QII | Long Answers Question (Answer any 1 out of 2) | 10 M |
| QII 1. | Long Answers Question (Answer any 1 out of 2)Explicate in detail the selection criteria for drug in design of sustained release drug delivery system. (LL5, C | |
| | | <i>YO2</i>) |
| 1. | Explicate in detail the selection criteria for drug in design of sustained release drug delivery system. (<i>LL5</i> , <i>C</i> | <i>YO2</i>) |
| 1. 2. | Explicate in detail the selection criteria for drug in design of sustained release drug delivery system. (<i>LL5</i> , <i>C</i> Elucidate in detail about different design approaches of matrix type-controlled release drug delivery system. (<i>LL5</i>) | 5, CO1) |
| 1. 2. Q.III | Explicate in detail the selection criteria for drug in design of sustained release drug delivery system. (<i>LL5</i> , <i>C</i> Elucidate in detail about different design approaches of matrix type-controlled release drug delivery system. (<i>LL5</i> Short Answers Question (Answer any 2 out of 3) - | 702) 5, CO1) |



Approved by AICTE, PCI, DTE, Affiliated to DBATU Lonere, MSBTE Mumbai

Vision: To pursue excellence in pharmaceutical education and research to develop competent professionals.

窗 (02562) 297802, 297602

www.svkm-iop.ac.in

 \square iopdhule@svkm.ac.in

First Sessional Theory Examination-(ODD SEM) 2023-2024

| Subject | : | Novel Drug Delivery Systems (BP704T) | Day & Date | : | Thur | sday, | 02/11/2023 |
|--------------|----------|--------------------------------------|--|---|------|---------------|---------------|
| Class | •• | Final Year B.Pharm | Semester | : | VIII | Write Here | Your Seat No. |
| Time | : | 2.30 pm – 4.00 pm | Max. Marks | : | 30 | пеге | |
| Instructions | 1. 3. | | 2. Draw a well label 4. Do not write/tick o | | | | |

| QI | Objective Type Questions $(5 \times 2) = 5 \times 2 = 10$ (Answer all the questions) | 10 M |
|-------------------|--|-----------------|
| 1. | Give the significance of elimination half-life $(t_{1/2})$ in design of controlled release formulation. (<i>LL3, CO1</i>) | |
| 2. | Differentiate the type of copolymer based on degree of reactivity between monomer. (<i>LL4, CO1</i>) | |
| 3. | Define the term :- i) Controlled Release (<i>LL1, CO1</i>) ii) Microencapsulation (<i>LL1, CO2</i>) | |
| 4. | Explain the principal difference between spray drying and spray congealing or Explain diffusion of drug by iontophoresis principle of permeation enhancement. (<i>LL3, CO2</i>) | |
| 5. | Enlist the principle involved in release of drug for implantable delivery system (<i>LL3</i> , <i>CO2</i>) | |
| | | |
| QII | Long Answers Question (Answer any 1 out of 2) | 10 M |
| QII 1. | Long Answers Question (Answer any 1 out of 2) Explicate in detail the selection criteria for drug in design of sustained release drug delivery system. (LL5, C | |
| | | <i>YO2</i>) |
| 1. | Explicate in detail the selection criteria for drug in design of sustained release drug delivery system. (<i>LL5</i> , <i>C</i> | <i>YO2</i>) |
| 1. 2. | Explicate in detail the selection criteria for drug in design of sustained release drug delivery system. (<i>LL5</i> , <i>C</i> Elucidate in detail about different design approaches of matrix type-controlled release drug delivery system. (<i>LL5</i>) | 5, CO1) |
| 1. 2. Q.III | Explicate in detail the selection criteria for drug in design of sustained release drug delivery system. (<i>LL5</i> , <i>C</i> Elucidate in detail about different design approaches of matrix type-controlled release drug delivery system. (<i>LL5</i> Short Answers Question (Answer any 2 out of 3) - | 702) 5, CO1) |



Approved by AICTE, PCI, DTE, Affiliated to DBATU Lonere, MSBTE Mumbai

Vision: To pursue excellence in pharmaceutical education and research to develop competent professionals.

窗 (02562) 297802, 297602

www.svkm-iop.ac.in

 \square iopdhule@svkm.ac.in

First Sessional Theory Examination-(ODD SEM) 2023-2024

| Subject | : | Novel Drug Delivery Systems (BP704T) | Day & Date | : | Thur | sday, | 02/11/2023 |
|--------------|----------|--------------------------------------|--|---|------|---------------|---------------|
| Class | •• | Final Year B.Pharm | Semester | : | VIII | Write Here | Your Seat No. |
| Time | : | 2.30 pm – 4.00 pm | Max. Marks | : | 30 | пеге | |
| Instructions | 1. 3. | | 2. Draw a well label 4. Do not write/tick o | | | | |

| QI | Objective Type Questions $(5 \times 2) = 5 \times 2 = 10$ (Answer all the questions) | 10 M | | | | | | |
|-------------------|--|-----------------|--|--|--|--|--|--|
| 1. | Give the significance of elimination half-life $(t_{1/2})$ in design of controlled release formulation. (<i>LL3, CO1</i>) | | | | | | | |
| 2. | Differentiate the type of copolymer based on degree of reactivity between monomer. (<i>LL4, CO1</i>) | | | | | | | |
| 3. | Define the term :- i) Controlled Release (<i>LL1</i> , <i>CO1</i>) ii) Microencapsulation (<i>LL1</i> , <i>CO2</i>) | | | | | | | |
| 4. | Explain the principal difference between spray drying and spray congealing or Explain diffusion of drug by iontophoresis principle of permeation enhancement. (<i>LL3, CO2</i>) | | | | | | | |
| 5. | Enlist the principle involved in release of drug for implantable delivery system (<i>LL3</i> , <i>CO2</i>) | | | | | | | |
| | | | | | | | | |
| QII | Long Answers Question (Answer any 1 out of 2) | 10 M | | | | | | |
| QII 1. | Long Answers Question (Answer any 1 out of 2) Explicate in detail the selection criteria for drug in design of sustained release drug delivery system. (LL5, C | | | | | | | |
| | | <i>YO2</i>) | | | | | | |
| 1. | Explicate in detail the selection criteria for drug in design of sustained release drug delivery system. (<i>LL5</i> , <i>C</i> | <i>YO2</i>) | | | | | | |
| 1. 2. | Explicate in detail the selection criteria for drug in design of sustained release drug delivery system. (<i>LL5</i> , <i>C</i> Elucidate in detail about different design approaches of matrix type-controlled release drug delivery system. (<i>LL5</i>) | 5, CO1) | | | | | | |
| 1. 2. Q.III | Explicate in detail the selection criteria for drug in design of sustained release drug delivery system. (<i>LL5</i> , <i>C</i> Elucidate in detail about different design approaches of matrix type-controlled release drug delivery system. (<i>LL5</i> Short Answers Question (Answer any 2 out of 3) - | 702) 5, CO1) | | | | | | |



Behind Gurudwara, Mumbai-Agra Highway, Dhule Phone: 02562- 297802, 297805 Fax: 02562- 287802, Email: examiop@svkm.ac.in

First Sessional Theory Examination 2020-2021

(Odd SEM)

Subject & Subject Code: Pharmacy Practice BP703T

Day & Date: Thursday 22/10/2020 Class: Final.Y.B.Pharma

Semester: VII Time: 1.30 P.M TO 3.00 P.M Max. Marks: 30

Instructions: 1. All questions are compulsory

2. Draw a well labeled diagram wherever necessary 3. Right hand side number indicates full marks

QI Multiple Choice Questions (MCQs)

10

- 1. Which of the following mentioned hospital setup based on the regionality
- a. Special hospitals
- b. Voluntary agency hospitals
- c. Allopathic hospital
- d. Upazila Health Complex

2. ______ is the head of administrative services belong to the pharmacy department

- a. COO
- b. Vice president
- c. Deputy General Manager
- d. CEO

3. This is extremely successful strategies for improving adherence minimization of adverse effects of medications

- a. Approach each patient individually to determine the level of adherence
- b. Dosing simplification
- c. Reviewing of every prescription and every order
- d. All of the above

4. The license for the retail sale of drugs other than the ones mentioned in the Schedule C, C1, and X is issued in

- a. Form No. 20
- b. Form No. 21
- c. Form No. 20A
- d. Form No. 21F

5. For Inpatient Department Doctor always write a drug order in_____

- a. Patient Home file
- b. Online prescription
- c. Drug Chart
- d. None of Above



Behind Gurudwara, Mumbai-Agra Highway, Dhule Phone: 02562- 297802, 297805 Fax: 02562- 287802, Email: examiop@svkm.ac.in

- 6. Decision for addition and deletion of the drug from hospital formulary is taken by
- a. Pharmacy manager
- b. Hospital Management
- c. Pharmacy Therapeutic Committee
- d. None of the above

7. Patient medication history interview provides valuable insights in_____

- a. Patient's allergic tendencies
- b. Adherence to pharmacological and non-pharmacological treatments
- c. Self-medication with complementary and alternative medicines
- d. All of the above

8. Use of drug concentration measurements in body fluids as an aid to the management of drug therapy for the cure is known as

- a. Medication Adherence
- b. Therapeutic Drug Monitoring
- c. Medication history Review
- d. Therapeutic Window

9. This is the Example of a tertiary source of drug information

- a. Review article
- b. PubMed
- c. Proceedings of conferences
- d. Pharmacopeias

10. This is a very crucial step of patient counseling to get Knowledge about his or her health problems and medications

- a. Introduction to patient
- b. Assessing the patient's condition
- c. Opening of session
- d. Closing of discussion

QII Long Answers (Answer any 1 out of 2)

1. Illustrate in detail about organization structure of Hospital Pharmacy and Explain location, the layout of OP Pharmacy along with staff requirement.

2. What do mean by drug distribution system, give the process design of drug distribution to the inpatient department.

QIII Short Answers (Answer any 2 out of 3)

1. Illustrate the adverse drug reaction and give its classification

2. Outline the causes of medication non-adherence and give role of pharmacist in the medication adherence

3. Give the design and constitution of the Pharmacy therapeutic Committee

10



Behind Gurudwara, Mumbai-Agra Highway, Dhule Phone: 02562- 297802, 297805 Fax: 02562- 287802, Email: examiop@svkm.ac.in

First Sessional Theory Examination 2021-2022 (Odd SEM) Subject & Subject Code: Pharmacy Practice BP703T

Day & Date: Wednesday 13/10/2021

Class: F.Y.B.Pharma

Time: 10.30 A.M TO 12.00 P.M

Semester: VII

Max. Marks: 30

Instructions: 1. All questions are compulsory 2. Draw a well labeled diagram wherever necessary

3. Right hand side number indicates full marks

QI Multiple Choice Questions (MCQs)

10

- 1. The concept of foundation of hospital was given by
- a. Indians
- b. Arabs c. Kiwis
- d. French

2. _ is the head of administrative services belong to the pharmacy department

- a. COO
- b. Vice president
- c. Deputy General Manager
- d. CEO

3. In India, under public health system medical colleges and advanced medical research institutes Provides

- a. Primary Care
- b. Secondary Care
- c. Tertiary Care
- d. None of these.

4. In layout deign of the hospital pharmacy restricted and non-restricted area mainly

- a. IP Pharmacy Services
- b. OP Pharmacy Services
- c. Both of Above
- d. None of Above

5. For Inpatient Department Doctor always write a drug order in_____

- a. Patient Home file
- b. Online prescription
- c. Drug Chart
- d. Physical Prescription

6. The hospital formulary system assists a drug under their non-proprietary or proprietary (brand) names in instance where drug have both names.

- a. Procuring
- b. Prescribing
- c. Dispensing
- d. All



Behind Gurudwara, Mumbai-Agra Highway, Dhule Phone: 02562- 297802, 297805 Fax: 02562- 287802, Email: examiop@svkm.ac.in

- 7. The hospital formulary is a list of _____preparations.
- a. Pharmaceutical
- b. Chemical
- c. Food
- d. None of these

8. Use of drug concentration measurements in body fluids as an aid to the management of drug therapy for the cure is known as

- a. Medication Adherence
- b. Medication history Review
- c. Therapeutic Drug Monitoring
- d. Therapeutic Window

9. _____is very educative and useful to the members of "Hearth Care Team".

- a. Formulary
- b. Pharmacopoeia
- c. Reference Book
- d. None of these

10. _____means how well the patient follows the instructions of when and how to take the medication.

- a. Description
- b. Instruction
- c. Compliance
- d. None of these

QII Long Answers (Answer any 1 out of 2)

1. Explain the adverse drug reaction give its classification and different categories of

ADR. Add a note on ADR Monitoring and reporting.

2. Explain about drug distribution system, give the process design of drug distribution

to the inpatient department inside hospital.

QIII Short Answers (Answer any 2 out of 3)

- 1. What is drug formulary and explain in detail about acquisition of drug formulary.
- 2. Explain in brief about Therapeutic Drug monitoring.
- 3. Give the design and constitution of the Pharmacy therapeutic Committee.

Subject-in-charge Mr. Sumit Rathod



Approved by AICTE, PCI and DTE; Affiliated to DBATU, Lonere and MSBTE Mumbai

Vision: To pursue excellence in pharmaceutical education and research to develop competent professionals.

🖾 (02562) 297802, 297602 🛛 🌐 www.svkm

www.svkm-iop.ac.in

⊠ iopdhule@svkm.ac.in

10 M

10 M

| First Sessional Theory Examination-(ODD SEM) 2023-2024 | | | | | | | | |
|--|---|----------------------------|------------|---|-----|-----------------------------|--|--|
| Subject | : | Pharmacy Practice (BP703T) | Day & Date | : | Wed | , 01/11/2023 | | |
| Class | : | Final Year B. Pharmacy | Semester | : | VII | | | |
| Time | : | 2.30 pm – 4:00 pm | Max. Marks | : | 30 | Write Your Seat No. Here | | |

Instructions: ¹. All questions are compulsory ². Draw a well-labeled diagram wherever necessary ³. Right-hand side number indicates full marks ⁴. Do not write/tick on the question paper

| Q. I: | Objective type questions (solve all questions) | 10 M |
|-------|---|------|
| 1 | Draw Well labelled diagram for inpatient pharmacy (IP Pharmacy) (CO1, LL2) | |
| 2 | What is drug interaction and enlist different types of drug interactions (CO1, LL4) | |
| 3 | Define hospital formulary and drug therapeutic committee (CO2, LL3) | |
| 4 | Enlist the name of a drug which required Therapeutic Drug Monitoring (CO2, LL3) | |
| 5a. | Give the causes for medication non-adherence (CO2, LL2) (1 mark) | |
| 5b. | Enlist the different licenses required for retail pharmacy (CO1, LL3) (1 mark) | |
| | | |

Q. II: Long Answers Questions (Answer any 1 out of 2)

1. Define the drug distribution system, and give the drug distribution process to OP Pharmacy. Add a short note on medication management procedure (MMP) (*CO1*, *LL5*)

2. Define adverse drug reactions and classification of ADR. Add a brief note on the Naranjo ADR probability assessment scale (*CO1*, *LL5*)

Q. III: Short Answers Questions (Answer any 2 out of 3)

1. Add a brief note on therapeutic drug monitoring (*CO2*, *LL4*)

2. Explain in brief about the patient medication history interview (CO2, LL4)

3. Explain in detail about location layout of retail pharmacy (CO2, LL3)



Approved by AICTE, PCI and DTE; Affiliated to DBATU, Lonere and MSBTE Mumbai

Vision: To pursue excellence in pharmaceutical education and research to develop competent professionals.

🖾 (02562) 297802, 297602 🛛 🌐 www.svkm

www.svkm-iop.ac.in

⊠ iopdhule@svkm.ac.in

10 M

10 M

| First Sessional Theory Examination-(ODD SEM) 2023-2024 | | | | | | | | |
|--|---|----------------------------|------------|---|-----|-----------------------------|--|--|
| Subject | : | Pharmacy Practice (BP703T) | Day & Date | : | Wed | , 01/11/2023 | | |
| Class | : | Final Year B. Pharmacy | Semester | : | VII | | | |
| Time | : | 2.30 pm – 4:00 pm | Max. Marks | : | 30 | Write Your Seat No. Here | | |

Instructions: ¹. All questions are compulsory ². Draw a well-labeled diagram wherever necessary ³. Right-hand side number indicates full marks ⁴. Do not write/tick on the question paper

| Q. I: | Objective type questions (solve all questions) | 10 M |
|-------|---|------|
| 1 | Draw Well labelled diagram for inpatient pharmacy (IP Pharmacy) (CO1, LL2) | |
| 2 | What is drug interaction and enlist different types of drug interactions (CO1, LL4) | |
| 3 | Define hospital formulary and drug therapeutic committee (CO2, LL3) | |
| 4 | Enlist the name of a drug which required Therapeutic Drug Monitoring (CO2, LL3) | |
| 5a. | Give the causes for medication non-adherence (CO2, LL2) (1 mark) | |
| 5b. | Enlist the different licenses required for retail pharmacy (CO1, LL3) (1 mark) | |
| | | |

Q. II: Long Answers Questions (Answer any 1 out of 2)

1. Define the drug distribution system, and give the drug distribution process to OP Pharmacy. Add a short note on medication management procedure (MMP) (*CO1*, *LL5*)

2. Define adverse drug reactions and classification of ADR. Add a brief note on the Naranjo ADR probability assessment scale (*CO1*, *LL5*)

Q. III: Short Answers Questions (Answer any 2 out of 3)

1. Add a brief note on therapeutic drug monitoring (*CO2*, *LL4*)

2. Explain in brief about the patient medication history interview (CO2, LL4)

3. Explain in detail about location layout of retail pharmacy (CO2, LL3)



Shri. Vile Parle Kelavani Mandal's

Institute of Pharmacy, Dhule Survey No. 499/1, Plot No.3, Behind Gurudwara, Mumbai Agra Highway

| Survey No. 499/1, Plot No.3, Dennia Gurudwara, Munibal Agra Highway | | | | | | | |
|---|--|------------|---------------------------|---------|--|--|--|
| | Second Sessional Theory Ex | | | | | | |
| Subje | | alysis | - | 12/2020 | | | |
| Class | 5 | | Semester : VII | | | | |
| Time | | | Max. Marks : 30 | | | | |
| | Instructions: 1. All questions are compulso | | | | | | |
| | 2. Draw a well labelled diagra | | | | | | |
| 0.1 | 3. Right hand side number ind | lıcates fi | ull marks | | | | |
| | Multiple Choice Questions | | | [10] | | | |
| 1 | One of the following do not represent Gel e | _ | | | | | |
| | a. Horizontal | | Vertical | | | | |
| | c. Diagonal | d. | All of the above | | | | |
| 11 | is highly sensitive method | 1 | | | | | |
| | a. GC | | HPLC | | | | |
| | c. TLC | | All of above | in | | | |
| 111 | In Gas Chromatography, is commo | oniy use | a as supporting material | ın | | | |
| | packed column | L | Distancessis | | | | |
| | a. Silica Gel c. a & b both | | Diatomaceous earth | | | | |
| : | | | None | | | | |
| 1V | Sephadex, an ion exchange resin based on a. Agarose | L | b. Dextrin | | | | |
| | c. Cellulose | | d. None | | | | |
| | In HPLC, the mobile phase should pass th | rough o | | | | | |
| v | a. 500-1000 psi | - | 0-300 psi | | | | |
| | c. 1000-3000psi | | 00-2500 psi | | | | |
| 171 | Size exclusion chromatography is also call | | 00 2000 psi | | | | |
| V I | a. Affinity chromatography | | per chromatography | | | | |
| | c. Thin layer chromatography | 0. 1a | None of the above | | | | |
| vii | Mild denaturating agents can be used to _ | | | | | | |
| • • • | | | | | | | |
| | a. attach macromolecule to | | move macromolecule from | 1 | | | |
| | ligand | | and | | | | |
| | c. a&b both | d. No | ne | | | | |
| viii | Rheodyne injector is used in | | | | | | |
| | a. HPLC | b. GC | | | | | |
| | c. HPTLC | | ne of above | | | | |
| ix | SDS-PAGE is technique used to separate proteins a | | | | | | |
| | a. nucleic motility | | ctrophoretic motility | | | | |
| | c. nucleic mobility | | ctrophoretic mobility | | | | |
| х | detector is not used in HPLC | | | | | | |
| | a. UV visible | b. Flı | lorescence | | | | |
| | c. Electrochemical | d. Ele | ectron Capture | | | | |
| | | | | | | | |
| Q.2. | Answer the following short questions (any | | | [10] | | | |
| а | Outline the principle, instrumentation and | l applica | ation used in Gel | | | | |
| | chromatography. | | | | | | |
| b | Discuss the classification, and mechanism | ı of actio | on of various ion exchang | e | | | |
| | resins. | | | | | | |
| с | Write short note on Affinity chromatograph | hv | | | | | |
| | | | | [10] | | | |
| Q.3. | Answer in detail of following (<i>any one</i>) | aigua E | valoin in detail about | [10] | | | |
| a | Depict the types of Chromatographic techn | - | - | | | | |
| | principle, instrumentation involved in Gas | Chrom | atography / HPLC. | | | | |

b Enlist the factors affecting electrophoretic mobility. Explain in details about methodologies and applications used in Paper and Capillary Electrophoresis.



Approved by AICTE, PCI, DTE, Affiliated to DBATU Lonere, MSBTE Mumbai

Vision: To pursue excellence in pharmaceutical education and research to develop competent professionals.

www.svkm-iop.ac.in

⊠ iopdhule@svkm.ac.in

Second Sessional Theory Examination-(ODD SEM) 2023-2024

| | Subject | : | Instrumental Methods of Analysis (BP701T) | Day & Date | : | Mon,1 | 8/12/2023 | | |
|-------------|------------------------|---|---|---|------|-----------|---------------|--|--|
| | Time | : | 02:30 pm – 04:00 pm | Max. Marks | : | 30 | | | |
| Instruction | ns: | | | w a well labeled diag ot write/tick on the q | - | | | | |
| Q. I. | Solve the | e fol | lowing questions | | | | 10 M | | |
| 1. | | | e Rf value if the distance travelled by so pectively. (CO3, LL5) | plute and solvent fr | om | origin li | ne are 3.7 cm | | |
| 2. | Why deriv | vati | zation techniques are required in GC? En | list derivatization n | neth | ods used | in GC. (CO3, | | |
| 3. | Enlist the /CO4, LL | | ctors affecting Rf value and factors affe | ecting Ion exchang | e se | paratior | a. (CO3, LL2, | | |
| 4. | Give the j | prir | ciple of affinity chromatography. | | | | | | |
| 5. | Different | iate | between normal phase and reversed pha | se chromatography | • | | | | |
| Q. II. | Long An | swe | ers Question (Answer any 1 out of 2) (| CO3, LL5) | | | 10 M | | |
| 1. | Explain th | he p | principle and instrumentation of Gas chro | omatography. | | | I | | |
| 2. | Explain th | he s | teps involved in TLC. Differentiate betw | veen Paper chromat | ogra | aphy and | I TLC. | | |
| Q. III. | Short An | ISW | ers Question (Answer any 2 out of 3) (| CO4, LL5) | | | 10 M | | |
| 1. | Write the | pri | nciple, types and applications of Ion exc | hange chromatogra | phy. | | 1 | | |
| 2. | | Draw a neat, labeled schematic diagram of HPLC. Give the advantages, disadvantages and applications of HPLC | | | | | | | |
| 3. | | | principle, methodology and applications | of size exclusion ch | rom | atograp | hy | | |



Approved by AICTE, PCI, DTE, Affiliated to DBATU Lonere, MSBTE Mumbai

Vision: To pursue excellence in pharmaceutical education and research to develop competent professionals.

🖾 (02562) 297802, 297602

www.svkm-iop.ac.in

⊠ iopdhule@svkm.ac.in

Mapping of Course Outcome with Second Sessional Theory Examination (2023-2024)

Subject: Instrumental Methods of Analysis (BP701T)

| Course Outcome | Question | Marks | |
|--|------------------|-------|--|
| C701.3: Understand the basics concept of chromatography as a separation technique and capable of distinguishing various | Q. I – 1, 2, 3 | | |
| techniques, principle and methodology of GC, TLC and Paper chromatography (<i>Level 5</i>) | Q. II – 1, 2, | 25 | |
| C701.3: Understand the fundamentals of various sophisticated | Q. I – 3, 4, 5 | | |
| instrumental technique like HPLC, Ion exchange, gel, affinity chromatography and can apply this knowledge to different sample analysis. (<i>Level 5</i>) | Q. III – 1, 2, 3 | 20 | |



Approved by AICTE, PCI, DTE, Affiliated to DBATU Lonere, MSBTE Mumbai

Vision: To pursue excellence in pharmaceutical education and research to develop competent professionals.

www.svkm-iop.ac.in

⊠ iopdhule@svkm.ac.in

Second Sessional Theory Examination-(ODD SEM) 2023-2024

| | Subject | : | Instrumental Methods of Analysis (BP701T) | Day & Date | : | Mon,1 | 8/12/2023 | | |
|-------------|------------------------|---|---|---|------|-----------|---------------|--|--|
| | Time | : | 02:30 pm – 04:00 pm | Max. Marks | : | 30 | | | |
| Instruction | ns: | | | w a well labeled diag ot write/tick on the q | - | | | | |
| Q. I. | Solve the | e fol | lowing questions | | | | 10 M | | |
| 1. | | | e Rf value if the distance travelled by so pectively. (CO3, LL5) | plute and solvent fr | om | origin li | ne are 3.7 cm | | |
| 2. | Why deriv | vati | zation techniques are required in GC? En | list derivatization n | neth | ods used | in GC. (CO3, | | |
| 3. | Enlist the /CO4, LL | | ctors affecting Rf value and factors affe | ecting Ion exchang | e se | paratior | a. (CO3, LL2, | | |
| 4. | Give the j | prir | ciple of affinity chromatography. | | | | | | |
| 5. | Different | iate | between normal phase and reversed pha | se chromatography | • | | | | |
| Q. II. | Long An | swe | ers Question (Answer any 1 out of 2) (| CO3, LL5) | | | 10 M | | |
| 1. | Explain th | he p | principle and instrumentation of Gas chro | omatography. | | | I | | |
| 2. | Explain th | he s | teps involved in TLC. Differentiate betw | veen Paper chromat | ogra | aphy and | I TLC. | | |
| Q. III. | Short An | ISW | ers Question (Answer any 2 out of 3) (| CO4, LL5) | | | 10 M | | |
| 1. | Write the | pri | nciple, types and applications of Ion exc | hange chromatogra | phy. | | 1 | | |
| 2. | | Draw a neat, labeled schematic diagram of HPLC. Give the advantages, disadvantages and applications of HPLC | | | | | | | |
| 3. | | | principle, methodology and applications | of size exclusion ch | rom | atograp | hy | | |



Approved by AICTE, PCI, DTE, Affiliated to DBATU Lonere, MSBTE Mumbai

Vision: To pursue excellence in pharmaceutical education and research to develop competent professionals.

🖾 (02562) 297802, 297602

www.svkm-iop.ac.in

⊠ iopdhule@svkm.ac.in

Mapping of Course Outcome with Second Sessional Theory Examination (2023-2024)

Subject: Instrumental Methods of Analysis (BP701T)

| Course Outcome | Question | Marks | |
|--|------------------|-------|--|
| C701.3: Understand the basics concept of chromatography as a separation technique and capable of distinguishing various | Q. I – 1, 2, 3 | | |
| techniques, principle and methodology of GC, TLC and Paper chromatography (<i>Level 5</i>) | Q. II – 1, 2, | 25 | |
| C701.3: Understand the fundamentals of various sophisticated | Q. I – 3, 4, 5 | | |
| instrumental technique like HPLC, Ion exchange, gel, affinity chromatography and can apply this knowledge to different sample analysis. (<i>Level 5</i>) | Q. III – 1, 2, 3 | 20 | |



Behind Gurudwara, Mumbai-Agra Highway, Dhule Phone: 02562- 297802, 297805 Fax: 02562- 287802, Email: examiop@svkm.ac.in

Second Sessional Examination 2020-2021 (ODD SEM)

Subject & Subject Code: Industrial Pharmacy II BP 702T **Class: Final Year B. Pharm** Time:1.30 - 3.00pm

Day & Date: Tuesday 11/11/2020 Semester: VII Max. Marks: 30

1. All questions are compulsory Instructions: 2. Draw a well labeled diagram wherever necessary

3. Right hand side number indicates full marks

QI Multiple Choice Questions (MCQs)

- 1. Which of the following is NOT needed for an investigational new drug application?
 - a. Animal pharmacology and toxicology b. Manufacturing information.
 - c. Clinical protocols and Investigator Information d. Phase III trial data
- 2. How many people will be selected for phase II trial?
 - a) 300-3000 people b. The whole market will be under surveillance c) 20-300 people d) 20-50 people
- 3. What is the term for the process that is used to prove that a drug is safe and effective in treating specific conditions in certain patient populations?
 - a. Drug discovery b. Preclinical development
 - c. The patent process d. Clinical development
- 4. In a six sigma improvement project the least experienced individuals are:
 - a. black belt b. green belt c. Red Belts d. Master Black Belts
- 5. DMAIC is _
 - a. develop, multiply, analyze, improve, check
 - b. define, muliply, analyze, improve, control
 - c. define, measure, analyze, improve, control
 - d. define, manufacture, analyze, improve, control
- 6. Deming's 4 step cycle for improvement is
 - a. plan, do, check, act
 - b. schedule, do, act, check
 - c. do, act, check, monitor
 - d. plan, control, act, sustain
- 7. A fishbone diagram is also known as a .
 - a. cause-and-effect diagram b. poka-yoke diagram
 - c. Kaizen diagram d. Taguchi diagram
- 8. Central drug Testing Laboratory is located at _ a. Kasauli b. Delhi c. Bangalore d. Lucknow
- 9. Which of the following is responsibility of state authority of CDSCO
 - a. Regulatory control over the import of drugs
 - b. Approval of new drugs and clinical trials

c. Meetings of Drugs Consultative Committee (DCC) and Drugs Technical Advisory Board (DTAB)

- d. Regulation of manufacture, sale and distribution of Drugs
- 10. Form 11 license is issued for
 - a. Export of drugs for examination, test or analysis
 - b. Manufacture of drugs for the purpose of examination, test or analysis
 - c. Import of drugs for examination, test or analysis
 - d. Distribution of drugs for examination, test or analysis



Behind Gurudwara, Mumbai-Agra Highway, Dhule Phone: 02562- 297802, 297805 Fax: 02562- 287802, Email: examiop@svkm.ac.in

QII Long Answers (Answer any 1 out of 2)

1. Describe in detail the New Drug Approval process.

2. Explain the concept of quality management systems in Pharmaceutical industry. Discuss various quality management tools.

QIII Short Answers (Answer any 2 out of 3)

- 1. Explain Quality by Design.
- 2. Write a note on Clinical Research Protocol.
- 3. Write down organizational structure, roles and responsibilities of CDSCO.

10



Behind Gurudwara, Mumbai-Agra Highway, Dhule Phone: 02562- 297802, 297805 Fax: 02562- 287802, Email: examiop@svkm.ac.in

Mapping of Course Outcome with Second Sessional Exam

| Course Outcome | Question | Marks |
|---|----------|-------|
| CO 702 3: Demonstrate the different laws and acts that | Q.1 – | |
| regulate pharmaceutical industry. Describe the approval | 1,2,3 | 18 |
| process and regulatory requirements of drug products. | Q 2 – 1 | |
| (Level 3) (Application) | Q 3- 1 | |
| CO 702 4: Explain the concept of quality management | Q 1 – | |
| systems in Pharmaceutical industry. Analyze and implement | 4,5,6,7 | 19 |
| various quality systems standards (Level 3) (Application) | Q 2 - 2 | |
| | Q 3 - 2 | |
| CO 702 5: Outline and describe the role and responsibility of | Q.1 – | |
| regulatory agencies in the approval of drugs. Discuss the | 8, 9, 10 | |
| organization and responsibilities of national and state | | 8 |
| licensing authority. | Q 3 - 3 | |
| (Level 1 & 2) (Knowledge & Comprehension) | | |



Approved by AICTE, PCI, DTE, Affiliated to DBATULonere, MSBTE Mumbai

Vision: To pursue excellence in pharmaceutical education and research to develop competent professionals.

🖾 (02562) 297802, 297602 🛛 🌐 www.svkr

💮 www.svkm-iop.ac.in

⊠ iopdhule@svkm.ac.in

| Subject: Industrial Pharmacy-II (BP702T)Class: Final Year B. PharmacyTime: 2.30 - 4.00pm | mination-(ODD SEM) 2023-2024 Day & Date :Tuesday, 19-12-2023 Semester : VII Max. Marks : 30 |
|--|---|
| 1. All questions are compulsInstructions:2. Draw a well labeled diago3. Right hand side number inQI Objective Type Questions (5 x 2) = 5 x 2 | ram wherever necessary ndicates full marks |
| 1. Enlist Historical milestones of Regulatory Affairs | (CO3, LL2) |
| 2. Write phases of clinical trials | (CO3, LL2) |
| 3. Define | (CO3, LL1, CO4, LL1) |
| a. NABL | b. Investigator's Brochure |
| 4. Enlist the responsibilities of CDSCO. | (CO4, LL1) |
| 5. Differentiate between ISO 9001 & ISO 14001 Series | (CO4, LL1) |
| QII Long Answers Question (Answer any 1 out of 2 | 2) (<i>CO3</i> , <i>LL4</i>) 10 M |
| 1. What is NDA? Give its significance and describe | process for NDA submission in USA and INDIA. |
| 2. Summarize about | |
| 1. Clinical research / BE studies, Clinical Re | esearch Protocols |
| 2. Explain role & responsibilities of Regulat | ory Affair Expert. |
| QII Short Answers Question (Answer any 2 out of | 3) (CO4, LL4) 10 M |
| 1. Illustrate various parameters of OOS. Write in br | ief about documentation. |

- 2. Summarize QMS in short
- 3. Explain in brief about COPP



Approved by AICTE, PCI, DTE, Affiliated to DBATU Lonere, MSBTE Mumbai

Vision: To pursue excellence in pharmaceutical education and research to develop competent professionals.

窗 (02562) 297802, 297602 www.svkm-iop.ac.in ⊠ iopdhule@svkm.ac.in Second Sessional Theory Examination-(ODD SEM) 2023-2024 Day & Date Industrial Pharmacy-II (BP702T) Subject : :Tuesday, 19-12-2023 Final Year B. Pharmacy Class Semester VII 30 Time Max. Marks 2.30 - 4.00pm : : 1. All questions are compulsory Instructions: 2. Draw a well labeled diagram wherever necessary З. Right hand side number indicates full marks 10 M QI Objective Type Questions $(5 \times 2) = 5 \times 2 = 10$ (Answer all the questions) 1. Enlist Historical milestones of Regulatory Affairs (CO3, LL2) 2. Write phases of clinical trials (CO3, LL2) 3. Define (CO3, LL1, CO4, LL1) a. NABL b. Investigator's Brochure 4. Enlist the responsibilities of CDSCO. (CO4, LL1) 5. Differentiate between ISO 9001 & ISO 14001 Series (CO4, LL1) OII Long Answers Question (Answer any 1 out of 2) (CO3, LL4) 10 M What is NDA? Give its significance and describe process for NDA submission in USA and INDIA. 1. 2. Summarize about

- 1. Clinical research / BE studies, Clinical Research Protocols
- 2. Explain role & responsibilities of Regulatory Affair Expert.
- QII Short Answers Question (Answer any 2 out of 3) (CO4, LL4) 10 M
- 1. Illustrate various parameters of OOS. Write in brief about documentation.
- 2. Summarize QMS in short
- 3. Explain in brief about COPP



Behind Gurudwara, Mumbai-Agra Highway, Dhule Phone: 02562- 297802, 297805 Fax: 02562- 287802, Email: examiop@svkm.ac.in

Second Sessional Theory Examination 2020-2021 (ODD SEM)

Subject & Subject Code: Novel Drug Delivery System (BP 704T)

Day & Date: Monday, 14/12/2020

Class: Final Year B.Pharm

Time: 1.30 – 3.00 pm

Semester: VII Max. Marks: 30

Instructions: 1. All questions are compulsory

2. Draw a well labeled diagram wherever necessary 3. Right hand side number indicates full marks

QI Multiple Choice Questions (MCQs)

1. The size range for nanoparticles drug delivery system is

- a. 1 10 nm
- b. 1 100 nm
- c. 1 1000 nm
- d. 100 1000 nm

2. The first report published byin 1902 describing targeted drug delivery system

- a. Dale E. Wurster
- b. Richard Feynman
- c. Paul Ehrlich
- d. Alexander Fleming
- 3. The primary route for absorption of drug through intraocular barriers
 - a. Corneal route
 - b. Conjunctival route
 - c. Scleral route
 - d. Systemic route
- 4. The effervescent components used to prepare floating drug delivery system
 - a. Sodium Carbonate
 - b. Citric acid
 - c. Tartaric acid
 - d. All of the above
- 5. The vesicular drug delivery system made up of nonionic surfactant is known as
 - a. Liposome
 - b. Niosomes
 - c. Nanoparticles
 - d. Monoclonal antibodies

6. The polar phosphate group linked with hydrophobic tail by a bridge of in phospholipid moiety

- a. Fatty acid chain
- b. Choline
- c. Ethanolamine
- d. Glycerol backbone



Behind Gurudwara, Mumbai-Agra Highway, Dhule Phone: 02562- 297802, 297805 Fax: 02562- 287802, Email: examiop@svkm.ac.in

7. Solvent present in inflatable chamber that gasifies at body temperature is

- a. Volatile oil
- b. Liquid ether
- c. Silicon oil
- d. Acetone
- 8. Which is not a type of Static intraocular barrier
 - a. Choroid
 - b. Cornea
 - c. Sclera
 - d. Retina
- 9. The limit for high density of Gastroretentive drug delivery system is
 - a. 2.5-3.0 gm/ml
 - b. 1.5-2.0 gm/ml
 - c. 0.5-1.0 gm/ml
 - d. 3.0-3.5 gm/ml

10. The rate controlling membrane in occusert is prepare by

- a. Hydroxy propyl methyl cellulose
- b. Ethylene Vinyl Acetate
- c. Cellulose acetate phthalate
- d. Gelatin

QII Long Answers (Answer any 1 out of 2)

1. Discuss in detail about intraoccular barriers, pre-corneal constraint and explain about design of occusert.

2. Describe in detail about carriers for targeted drug delivery system and give mechanism

of liposome formation.

QIII Short Answers (Answer any 2 out of 3)

- 1. Explain in brief about copper bearing intrauterine drug delivery system.
- 2. Discuss in brief about method of nanoparticle preparation.
- 3. Illustrate in brief about ligands for targeted drug delivery system.

10



Behind Gurudwara, Mumbai-Agra Highway, Dhule Phone: 02562- 297802, 297805 Fax: 02562- 287802, Email: examiop@svkm.ac.in

Mapping of Course Outcome with Second Sessional Exam

| Course Outcome | Question | Marks |
|--|---------------|-------|
| CO 7041: Outline and discuss the basic components and formulation approaches for Novel Drug Delivery System viz | Q.1-4,7,9 | |
| CDDS, TDDS, GRDDS, Nasopulmonary and IUD - Level 2 (Comprehension) | Q 3 – 1 | 08 |
| CO 7044: Demonstrate molecular aspect of targeted drug | Q 1 – 1,2,5,6 | |
| delivery system and discuss about liposome, niosome and nanoparticle – Level 3 & 2 (Application & Comprehension) | Q 2 - 2 | 24 |
| | Q 3 – 2,3 | |
| CO 7045: Extrapolate significance of intra ocular barriers in | Q.1 – 3,8,10 | |
| absorption of drug in eye, design and development of novel ocular formulations – ocuserts - Level 2 & 3 | Q 2 - 1 | 13 |
| (Comprehension & Application) | | |



Behind Gurudwara, Mumbai-Agra Highway, Dhule Phone: 02562- 297802, 297805 Fax: 02562- 287802, Email: examiop@svkm.ac.in

Second Sessional Theory Examination 2020-2021 (ODD SEM)

Subject & Subject Code: Novel Drug Delivery System (BP 704T)

Day & Date: Monday, 14/12/2020

Class: Final Year B.Pharm

Time: 1.30 – 3.00 pm

Semester: VII Max. Marks: 30

Instructions: 1. All questions are compulsory

2. Draw a well labeled diagram wherever necessary 3. Right hand side number indicates full marks

QI Multiple Choice Questions (MCQs)

1. The size range for nanoparticles drug delivery system is

- a. 1 10 nm
- b. 1 100 nm
- c. 1-1000 nm
- d. 100 1000 nm

2. The first report published byin 1902 describing targeted drug delivery system

- a. Dale E. Wurster
- b. Richard Feynman
- c. Paul Ehrlich
- d. Alexander Fleming
- 3. The primary route for absorption of drug through intraocular barriers
 - a. Corneal route
 - b. Conjunctival route
 - c. Scleral route
 - d. Systemic route
- 4. The effervescent components used to prepare floating drug delivery system
 - a. Sodium Carbonate
 - b. Citric acid
 - c. Tartaric acid
 - d. All of the above
- 5. The vesicular drug delivery system made up of nonionic surfactant is known as
 - a. Liposome
 - b. Niosomes
 - c. Nanoparticles
 - d. Monoclonal antibodies

6. The polar phosphate group linked with hydrophobic tail by a bridge of in phospholipid moiety

- a. Fatty acid chain
- b. Choline
- c. Ethanolamine
- d. Glycerol backbone



Behind Gurudwara, Mumbai-Agra Highway, Dhule Phone: 02562- 297802, 297805 Fax: 02562- 287802, Email: examiop@svkm.ac.in

7. Solvent present in inflatable chamber that gasifies at body temperature is

- a. Volatile oil
- b. Liquid ether
- c. Silicon oil
- d. Acetone
- 8. Which is not a type of Static intraocular barrier
 - a. Choroid
 - b. Cornea
 - c. Sclera
 - d. Retina
- 9. The limit for high density of Gastroretentive drug delivery system is
 - a. 2.5-3.0 gm/ml
 - b. 1.5-2.0 gm/ml
 - c. 0.5-1.0 gm/ml
 - d. 3.0-3.5 gm/ml

10. The rate controlling membrane in occusert is prepare by

- a. Hydroxy propyl methyl cellulose
- b. Ethylene Vinyl Acetate
- c. Cellulose acetate phthalate
- d. Gelatin

QII Long Answers (Answer any 1 out of 2)

1. Discuss in detail about intraoccular barriers, pre-corneal constraint and explain about design of occusert.

2. Describe in detail about carriers for targeted drug delivery system and give mechanism

of liposome formation.

QIII Short Answers (Answer any 2 out of 3)

- 1. Explain in brief about copper bearing intrauterine drug delivery system.
- 2. Discuss in brief about method of nanoparticle preparation.
- 3. Illustrate in brief about ligands for targeted drug delivery system.

10



Behind Gurudwara, Mumbai-Agra Highway, Dhule Phone: 02562- 297802, 297805 Fax: 02562- 287802, Email: examiop@svkm.ac.in

Mapping of Course Outcome with Second Sessional Exam

| Course Outcome | Question | Marks |
|--|---------------|-------|
| CO 7041: Outline and discuss the basic components and formulation approaches for Novel Drug Delivery System viz | Q.1-4,7,9 | |
| CDDS, TDDS, GRDDS, Nasopulmonary and IUD - Level 2 (Comprehension) | Q 3 – 1 | 08 |
| CO 7044: Demonstrate molecular aspect of targeted drug | Q 1 – 1,2,5,6 | |
| delivery system and discuss about liposome, niosome and nanoparticle – Level 3 & 2 (Application & Comprehension) | Q 2 - 2 | 24 |
| | Q 3 – 2,3 | |
| CO 7045: Extrapolate significance of intra ocular barriers in | Q.1 – 3,8,10 | |
| absorption of drug in eye, design and development of novel ocular formulations – ocuserts - Level 2 & 3 | Q 2 - 1 | 13 |
| (Comprehension & Application) | | |



Approved by AICTE, PCI, DTE, Affiliated to DBATULonere, MSBTEMumbai

Vision: To pursue excellence in pharmaceutical education and research to develop competent professionals.

www.svkm-iop.ac.in

 \square iopdhule@svkm.ac.in

Second Sessional Theory Examination-(ODD SEM) 2023-2024

| Subject | : | Novel Drug Delivery Systems (BP704T) | Day & Date | : | Thur | sday, | 21/12 | 2/20 | 23 |
|--------------|------------|--------------------------------------|---|---|------|-------|-------|-------|-----|
| Class | : | Final Year B.Pharm | Semester | : | VIII | | Your | Seat | No. |
| Time | : | 2.30 pm – 4.00 pm | Max. Marks | : | 30 | Here | | | |
| Instructions | s:1. 3. | | 2. Draw a well label . Do not write/tick o | | | | | ssary | , |

| QI | Objective Type Questions $(5 \times 2) = 5 \times 2 = 10$ (Answer all the questions) | 10 M | | |
|-------|---|-----------|--|--|
| 1. | Give the mechanism of drug absorption for pulmonary drug delivery system. (LL3, CO3) | | | |
| 2. | Explain in brief about the novel ophthalmic insert - occusert. (LL2, CO3) | | | |
| 3. | Name the polymer used in formulation of :- i) Intra-uterine devices (<i>LL1</i> , <i>CO3</i>) ii) Liposome (<i>LL1</i> , <i>CO4</i>) | | | |
| 4. | Explain in detail about the carriers used in targeted drug delivery system (LL2, CO4) | | | |
| 5. | Describe about active targeting approach at molecular level (<i>LL3</i> , <i>CO4</i>) | | | |
| QII | Long Answers Question (Answer any 1 out of 2) | 10 M | | |
| 1. | Differentiate between nasal and pulmonary system and explain the formulation of nasal system or dry powder inhaler (<i>LL4, CO3</i>) | | | |
| 2. | Elucidate in detail about different design approaches of floating type gastroretentive drug delivery system. (I | LL5, CO3) | | |
| Q.III | Short Answers Question (Answer any 2 out of 3) - | 10M | | |
| 1. | Describe about the principle involved in formulation of liposome (<i>LL3, CO4</i>) | | | |
| 2. | Illustrate in brief about passive targeting method through PEGylation or Write a note on Monoclonal antibodies (<i>LL3</i> , <i>CO4</i>) | | | |
| 3. | Describe in brief about Niosome or Nanopaticle (<i>LL2, CO4</i>) | | | |

Checked By

Verified By



Approved by AICTE, PCI, DTE, Affiliated to DBATU Lonere, MSBTE Mumbai

Vision: To pursue excellence in pharmaceutical education and research to develop competent professionals.

窗 (02562) 297802, 297602

www.svkm-iop.ac.in

 \square iopdhule@svkm.ac.in

Second Sessional Theory Examination-(ODD SEM) 2023-2024

| Subject | : | Novel Drug Delivery Systems (BP704T) | Day & Date | : | Thur | sday, | 21/12 | 2/202 | 23 |
|--------------|----------|--------------------------------------|--|---|------|-------|--------|-------|-----|
| Class | : | Final Year B.Pharm | Semester | : | VIII | | Your S | Seat | No. |
| Time | : | 2.30 pm – 4.00 pm | Max. Marks | : | 30 | Here | | | |
| Instructions | 1. 3. | | 2. Draw a well label 4. Do not write/tick o | | | | | ssary | |

| QI | Objective Type Questions $(5 \times 2) = 5 \times 2 = 10$ (Answer all the questions) | 10 M | | | |
|-------|---|------------|--|--|--|
| 1. | Give the mechanism of drug absorption for pulmonary drug delivery system. (LL3, CO3) | | | | |
| 2. | Explain in brief about the novel ophthalmic insert - occusert. (LL2, CO3) | | | | |
| 3. | Name the polymer used in formulation of :- i) Intra-uterine devices (<i>LL1, CO3</i>) ii) Liposome (<i>LL1, CO4</i>) | | | | |
| 4. | Explain in detail about the carriers used in targeted drug delivery system (LL2, CO4) | | | | |
| 5. | Describe about active targeting approach at molecular level (<i>LL3, CO4</i>) | | | | |
| QII | Long Answers Question (Answer any 1 out of 2) | 10 M | | | |
| 1. | Differentiate between nasal and pulmonary system and explain the formulation of nasal system or dry powde (<i>LL4</i> , <i>CO3</i>) | er inhaler | | | |
| 2. | Elucidate in detail about different design approaches of floating type gastroretentive drug delivery system. (<i>LL5, CO3</i>) | | | | |
| Q.III | IShort Answers Question (Answer any 2 out of 3)10M | | | | |
| 1. | Describe about the principle involved in formulation of liposome (<i>LL3, CO4</i>) | | | | |
| 2. | Illustrate in brief about passive targeting method through PEGylation or Write a note on Monoclonal antibodies (<i>LL3</i> , <i>CO4</i>) | | | | |
| 3. | Describe in brief about Niosome or Nanopaticle (<i>LL2</i> , <i>CO4</i>) | | | | |

Checked By



Behind Gurudwara, Mumbai-Agra Highway, Dhule Phone: 02562- 297802, 297805 Fax: 02562- 287802, Email: examiop@svkm.ac.in

Second Sessional Theory Examination 2020-2021

(Odd SEM)

Subject & Subject Code: Pharmacy Practice BP703TDay & Date: Thursday 12/12/2020Class: F.Y.B.PharmaSemester: VIITime: 1.30 P.M TO 3.00 P.MMax. Marks: 30

Instructions: 1. All questions are compulsory

2. Draw a well labeled diagram wherever necessary 3. Right hand side number indicates full marks

3. Right hand side humber thatcales juli ma

QI Multiple Choice Questions (MCQs)

10

1. This is a very crucial step of patient counseling to get Knowledge about his or her health problems and medications

- A. Introduction to patient
- B. Assessing the patient's condition
- C. Opening of session
- D. Closing of discussion

2. _____ is in house training programs usually start after deputation of staff to their working department location only.

- A. OJT
- B. New Hire Training
- C. Continuous Education Programme
- D. None of above

3. hs^a is abbreviation used during prescribed of medication is indicate

- A. Immediate at once
- B. Every other day
- C. At the bed time
- D. None of Above
- 4. Duration of long budget preparation is
- A. 2 years
- B. 5-10 years
- C. 3-6 years
- D. 15 years

5. To recognize untreated health problems that could be improved or resolved with appropriate medication therapy is important function of

- A. Clinical pharmacist
- B. Nursing staff
- C. Dispensing pharmacist
- D. Physician

6. Fallowing is example for over the counter OTC drugs

- A. Itraconazole
- B. Rantac
- C. Corex
- D. Itch guard



Behind Gurudwara, Mumbai-Agra Highway, Dhule Phone: 02562- 297802, 297805 Fax: 02562- 287802, Email: examiop@svkm.ac.in

7. ROL= (a × n) + B.S is formula used for calculating Maximum stock level Reorder level
Zero order level
Minimum order level

8. The storage of pharmaceutical product at cool temperature need to store

- at____temperature
- A. 2-8°C
- B. 8-25°C
- C. 30-40°C
- D. 40°C

9. This category consist of investigational use drugs, which have passed through the preliminary research stage

Class A Class B

Class C

Class D

10. A biochemical test result means that the substance or condition being tested for was found is known as

- A. Inconclusive test
- B. A negative test
- C. A positive test
- D. None of above

QII Long Answers (Answer any 1 out of 2)

1. Explain the concept of clinical pharmacy, give functions and responsibilities of clinical pharmacist add a note on medication chart review.

2. Explain in detail about principle, procedure for purchase and inventory control. Add a short note on methods used for the analysis of the drug expenditure.

QIII Short Answers (Answer any 2 out of 3)

1. Explain in brief Internal and external training program carried out in hospitals

- 2. Illustrate in brief about clinical laboratory tests and their interpretation of results
- 3. Elucidate about over the counter (OTC) sales

10



Approved by AICTE, PCI and DTE; Affiliated to DBATU, Lonere and MSBTE Mumbai

Vision: To pursue excellence in pharmaceutical education and research to develop competent professionals.

🖾 (02562) 297802, 297602 🛛 🌐 www.svkm-iop.ac.in

⊠ iopdhule@svkm.ac.in

| Second Sessional Theory Examination-(ODD SEM) 2023-2024 | | | | | | |
|---|---|----------------------------|------------|-------------------------------------|--|--|
| Subject | : | Pharmacy Practice (BP703T) | Day & Date | : Wed, 20/12/2023 | | |
| Class | : | Final Year B. Pharmacy | Semester | : VII | | |
| Time | : | 2.30 pm – 4:00 pm | Max. Marks | : 30 Write Your Seat No. Here | | |

Instructions: 1. All questions are compulsory 2. Draw a well-labeled diagram wherever necessary 3. Right-hand side number indicates full marks 4. Do not write/tick on the question paper Q. I: Objective-type questions (solve all questions) 10 M Give the list of members of the Pharmacy Therapeutic Committee (CO3, LL2) 1 Give the information about the green color pages of CIMS (CO3, LL4) 2 Give the full form of abbreviations: O.D., A.S., A.U, and DISC (CO4, LL3) 3 4 Give the normal range value of blood potassium, BUN, and blood glucose along with unit (CO4, *LL3*) What is the formula for calculating reorder level inventory (ROL)? (CO3, LL2) 5a. (1 mark) What is MCV and MCHC (CO4, LL3) (1 mark) 5b. Q. II: Long Answers Questions (Answer any 1 out of 2) 10 M 1. Define clinical pharmacy, give the function of a clinical pharmacist, and explain with suitable example pharmacist intervention (CO3, LL5) 2. What is the investigational use of drugs? Give its principle. Explain in detail about the classification of Investigational drugs (CO3, LL6) Q. III: Short Answers Questions (Answer any 2 out of 3) **10 M** 1. Add a brief note on over-the-counter medications (CO4, LL4) 2. Explain in detail about various steps involved in the patient counseling (CO4, LL4) 3. Explain in detail about blood chemistry test (CO4, LL3)



Approved by AICTE, PCI and DTE; Affiliated to DBATU, Lonere and MSBTE Mumbai

Vision: To pursue excellence in pharmaceutical education and research to develop competent professionals.

🖾 (02562) 297802, 297602 🛛 🌐 www.svkm-iop.ac.in

⊠ iopdhule@svkm.ac.in

| Second Sessional Theory Examination-(ODD SEM) 2023-2024 | | | | | | |
|---|---|----------------------------|------------|-------------------------------------|--|--|
| Subject | : | Pharmacy Practice (BP703T) | Day & Date | : Wed, 20/12/2023 | | |
| Class | : | Final Year B. Pharmacy | Semester | : VII | | |
| Time | : | 2.30 pm – 4:00 pm | Max. Marks | : 30 Write Your Seat No. Here | | |

Instructions: 1. All questions are compulsory 2. Draw a well-labeled diagram wherever necessary 3. Right-hand side number indicates full marks 4. Do not write/tick on the question paper Q. I: Objective-type questions (solve all questions) 10 M Give the list of members of the Pharmacy Therapeutic Committee (CO3, LL2) 1 Give the information about the green color pages of CIMS (CO3, LL4) 2 Give the full form of abbreviations: O.D., A.S., A.U, and DISC (CO4, LL3) 3 4 Give the normal range value of blood potassium, BUN, and blood glucose along with unit (CO4, *LL3*) What is the formula for calculating reorder level inventory (ROL)? (CO3, LL2) 5a. (1 mark) What is MCV and MCHC (CO4, LL3) (1 mark) 5b. Q. II: Long Answers Questions (Answer any 1 out of 2) 10 M 1. Define clinical pharmacy, give the function of a clinical pharmacist, and explain with suitable example pharmacist intervention (CO3, LL5) 2. What is the investigational use of drugs? Give its principle. Explain in detail about the classification of Investigational drugs (CO3, LL6) Q. III: Short Answers Questions (Answer any 2 out of 3) **10 M** 1. Add a brief note on over-the-counter medications (CO4, LL4) 2. Explain in detail about various steps involved in the patient counseling (CO4, LL4) 3. Explain in detail about blood chemistry test (CO4, LL3)